The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to...
- The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing shortage in the United States.
Attention deficit hyperactivity disorder drugs have been in short supply for years. The FDA warned of a shortage of Israel-based drugmaker Teva Pharmaceutical Industries' Adderall in October 2022, troubled by manufacturing delays.Vyvanse, also known as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, and additional prescribing safeguards are put in place.
Generic Drug Generic Medication Abuse UK Site Content United Kingdom Site Content United Kingdom UK
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US envoy defends anti-drug cooperation with Mexico amid neighbor's complaint on drug capo surrenderThe U.S. ambassador to Mexico is defending cross-border anti-drug cooperation after Mexican prosecutors complained the Americans aren't giving them enough information. Mexico's government was embarrassed by the surrender of two Mexican drug lords who arrived in Texas aboard a mysterious flight in July.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease. But the U.K.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease.
Read more »
UK drug regulator approves Alzheimer's drug but government likely won't pay for itBritain’s drug regulator has authorized the Alzheimer’s drug Leqembi, saying that it’s the first medicine to show some impact in slowing progression of the neurodegenerative disease
Read more »